Intelligent Bio Advances FDA 510(k) with Cybersecurity

NEW YORK, April 17, 2026

Intelligent Bio Solutions Inc. (INBS) has strengthened its upcoming FDA 510(k) submission by successfully completing independent penetration testing, confirming that its drug screening technology contains no major cybersecurity vulnerabilities. This milestone underscores the company’s commitment to data integrity, device security, and regulatory compliance, positioning its fingerprint-based drug screening system as a robust and reliable solution in the evolving landscape of medical device cybersecurity and diagnostics innovation.

Cybersecurity Validation Strengthens Regulatory Readiness

The completion of penetration testing represents a critical step in aligning with FDA cybersecurity expectations for medical devices, ensuring that systems are resilient against potential threats. The independent assessment verified the strength and reliability of INBS’s security infrastructure, confirming that the platform meets stringent standards required for regulatory submission.

In response to evolving regulatory requirements, the company has also implemented enhanced security architecture, including encrypted identification tags to safeguard test integrity and firmware protection mechanisms that restrict unauthorized updates. These upgrades ensure that the system maintains secure operation throughout its lifecycle, protecting both device performance and sensitive donor data.

By proactively addressing cybersecurity concerns, INBS is demonstrating compliance with FDA guidance on premarket submissions, where data protection and system integrity have become essential evaluation criteria. This positions the company to navigate the regulatory process more efficiently while reducing potential approval delays.

Innovative Fingerprint Drug Testing Technology

At the core of INBS’s offering is its Intelligent Fingerprinting Drug Screening System, a non-invasive, rapid diagnostic solution that analyzes fingerprint sweat to detect recent drug use. The system is capable of identifying substances such as opioids, cocaine, methamphetamine, and cannabis, delivering results in under ten minutes with minimal sample collection time.

This technology offers significant advantages over traditional drug testing methods, including improved hygiene, ease of use, and faster turnaround times, making it particularly valuable in safety-critical industries such as construction, transportation, and manufacturing. Its portability and efficiency enable on-site testing, reducing operational disruptions and enhancing workplace safety.

The integration of secure digital architecture with diagnostic capability highlights a growing trend in next-generation medical devices, where cybersecurity and clinical functionality are equally prioritized. This dual focus is increasingly important as healthcare systems adopt more connected and data-driven technologies.

Expanding Opportunities in the U.S. Diagnostics Market

With the FDA 510(k) submission progressing, INBS is targeting entry into the multi-billion-dollar U.S. drug screening market, where demand for rapid, reliable, and secure testing solutions continues to grow. Successful clearance would enable the company to expand its commercial footprint and leverage its technology across multiple sectors, including workplace safety, healthcare, and law enforcement.

The company’s proactive approach to cybersecurity compliance not only strengthens its regulatory position but also enhances its competitive advantage in a market increasingly focused on data security and system reliability. As regulatory agencies place greater emphasis on secure-by-design medical technologies, INBS’s advancements position it at the forefront of this shift.

The successful completion of penetration testing marks a significant milestone for Intelligent Bio Solutions, reinforcing the importance of cybersecurity in modern medical device development. By combining innovative diagnostic technology with robust security infrastructure, the company is advancing toward FDA clearance while addressing critical industry needs for secure, rapid, and non-invasive drug testing solutions.

Source: Intelligent Bio Solutions press release